PUBLISHED DATE : Aug 2022 | Pages : 222
Fill out your details & get your free sample
The Ulcerative Colitis Market Size, Share, Trends Analysis
Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2022-2027
222 Pages
8 Tables
160 Charts
3 Regions
8 Countries
10 Companies
4 Market Segment
| Report Attribute | Details |
|---|---|
| Market Size (2027) | USD 12 Billion |
| Market Size (2021) | USD 7.24 Billion |
| CAGR (2022-2027) | 8.77% |
| Base Year | 2021 |
| Forecast Year | 2022-2027 |
| Market Segments | Drug Class, Gender Type, Disease Type, and Geography |
| Geographic Analysis | North America, Europe, and APAC |
| Countries Covered | US, France, Germany, Italy, UK, Spain, China, and Japan |
The ulcerative colitis market was valued at USD 7.24 billion in 2021 and is expected to reach USD 12 Billion by 2027, growing at a CAGR of 8.77% from 2022 to 2027. Ulcerative colitis is a chronic inflammatory bowel disease (IBD) in which abnormal immune system reactions cause inflammation and ulcers on the inner lining of the large intestine. The ulcerative colitis epidemiology provides insights into the historical and current patient pools and forecasted trends for eight (8MM) major countries. The ulcerative colitis segment covers the historical and forecasted epidemiology data in the US, EU5 (including France, Germany, Italy, Spain, and the UK), China, and Japan from 2021-2027. The Ulcerative colitis epidemiology data are studied through all possible divisions to give a better understanding of the disease scenario in 8MM.
This report provides a detailed analysis of the drugs available for treating ulcerative colitis. The report covers a detailed drug description, including drug name, sponsor name, route of administration, molecule type, mechanism of action of the drug, clinical studies, NDA approvals, and Ulcerative colitis (Ulcerative colitis) collaborations, licensing, mergers and acquisition, designations, and other product-related details.
According to Arizton's estimate, the diagnosed incident cases of inflammatory bowel disease were high in the United States, followed by China and the UK in 2020. The increasing prevalence of ulcerative colitis is driving the growth of the ulcerative colitis drug market. According to the estimates, one million people were affected by inflammatory bowel disease in the US in 2019.
Launch of New Therapies: The USFDA approved small molecules such as Jyseleca (Filgotinib) and Rinvoq (Upadacitinib) in 2022 to treat moderate-to-severe ulcerative colitis. The launch of approved small molecules and further uptake in biological therapies will lead to significant growth in the ulcerative colitis therapeutics market.
Increasing Prevalence of Ulcerative Colitis: The market studied has been witnessing considerable growth, which is attributed to the increasing prevalence of inflammatory bowel disease worldwide. According to the estimates, the prevalence of inflammatory bowel disease patients was 910,000 in the United States in 2018.
High Investment in R&D Activities: Major players in the market are developing products and spending significantly on research and development, along with major acquisitions and collaborations to achieve a competitive edge over their counterparts. High investments in R&D capabilities and infrastructure by the industry and governments are anticipated to create lucrative opportunities in the market.
Presence of Major Players: Companies such as AbbVie, Inc., Pfizer, Inc., Janssen Biotech, Inc. (Johnson & Johnson) are among the major players in the global ulcerative colitis treatment market. These players are focused on adopting organic and inorganic growth strategies to strengthen their product portfolio.
These companies have adopted strategies such as collaborations & acquisitions, expansion of geographical footprint, investments in research & development, and manufacture of novel drugs to compete in the global ulcerative colitis treatment market. The other prominent players operating in the global ulcerative colitis market include Allergan plc, Bausch Health Companies Inc., Takeda Pharmaceutical Company Limited, Novartis AG, Galapogos, and Seres Therapeutics.
The US dominates the ulcerative colitis market due to the rise in healthcare affordability in the US, the rise in knowledge and awareness amongst the people, and the technological advancement in this region. However, the UK is expected to grow at a faster rate with a high CAGR in the ulcerative colitis drug market due to a rise in access and quality of healthcare, an increase in awareness about disease management, and rising healthcare expenditure in this region. The trend of biosimilars in emerging markets, such as China and Japan, could potentially alter the therapeutic landscape in this region.
Drug Class: Among the drug class, TNF-Alpha inhibitors are expected to account for a significant share of the global ulcerative colitis therapeutics market. However, the other class of drugs is expected to be the fastest-growing segment during the forecast period. Recently approved small molecules such as Jyseleca (filgotinib) and Rinvoq (upadacitinib) are expected to drive the global ulcerative colitis market during the forecast period.
Gender type: Among the gender type, Men were expected to account for a significant share of the global ulcerative colitis market. This is due to men being more likely affected than women.
Disease type: Among the Disease type, Total colitis is expected to account for significant ulcerative colitis market share. However, Proctitis is expected to be the fastest-growing segment during the forecast period.
The portfolio contains a total of 106+ assets in various development phases. Most industry-sponsored drugs in active clinical development for ulcerative colitis are in the Phase II stage.
The clinical trial portfolio contains 155+ trials in various development phases. Most industry-sponsored drugs in active clinical development for inflammatory bowel disease are in Phase II, with three drugs in the NDA/BLA stage. The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for ulcerative colitis have been in the early and mid-phases of development, with 84% of trials in Phase I-II and only 16% in Phase III-IV. The US has a substantial lead in the number of ulcerative colitis clinical trials globally.
The Ulcerative Colitis market is dominated by companies offering generic drugs and selective pharma/biotech companies offering patented/commercial drugs for treating IBD. The US Food and Drug Administration (FDA) approved the TNF-Alpha agent Humira (Adalimumab) for treating ulcerative colitis in 2012. This marked the arrival of biologics in this treatment landscape. Following this, the FDA approved Jyseleca (filgotinib) and Rinvoq (upadacitinib) in 2022 and Zeposia (ozanimod) in 2021 for the treatment of UC. Although generic products continue to capture significant market share, the arrival of biologics and other targeted therapies indicates a paradigm shift in this therapeutic space through the forecast period.
The inflammatory bowel disease therapeutics portfolio contains a total of 106+ assets in various development phases. Some late-stage emerging inflammatory bowel disease Therapeutics include AJM-300, ontamalimab, CT-P13 SC, SHR-0302, mirikizumab, and others. Launching these novel emerging drugs will shift the inflammatory bowel disease treatment paradigm shortly. With more than 106 molecules in various stages of development, it is expected that new vendors are likely to enter the market with novel mechanisms of action and better safety and efficacy profiles compared to the existing patented commercial drugs for treating ulcerative colitis. Key vendors are likely to face stiff competition from emerging players whose drugs are in various stages of development for UC. Existing vendors need to compete with more than 90 vendors post the approval of their investigational molecules for inflammatory bowel disease treatment in the coming years.
The prominent players offering drugs in the market include Takeda, Abbvie, Janssen Pharmaceuticals, Pfizer, Bristol-Myers-Squibb, EA Pharma Co Ltd, Celltrion, ReiStone Biopharma, Eli Lilly and Company, and Index Pharmaceuticals. These players are focused on R&D initiatives to develop technologically advanced and innovative inflammatory bowel disease treatment drugs and are also entering into collaborations to maintain their market position.
Frequently Asked Questions
HOW BIG IS THE GLOBAL ULCERATIVE COLITIS MARKET?
The global ulcerative colitis market is expected to reach USD 12 billion by 2027.
WHAT IS THE GROWTH RATE OF THE GLOBAL ULCERATIVE COLITIS MARKET?
The global ulcerative colitis market is expected to grow at a CAGR of 8.77% from 2022 to 2027.
WHO ARE THE KEY PLAYERS IN THE ULCERATIVE COLITIS (UC) MARKET?
Johnson & Johnson, AbbVie Inc (AbbVie), Takeda Pharmaceutical Co Ltd (Takeda), Pfizer Inc (Pfizer), Bristol-Myers Squibb, EA Pharma, Eli Lilly and Company, InDex Pharmaceuticals, Reistone Biopharma Co. Ltd., and CellTrion.
WHAT ARE THE GROWTH FACTORS IN THE ULCERATIVE COLITIS MARKET?
The launch of new therapies and the high prevalence of ulcerative colitis is the growth factors in the market.
The ulcerative colitis market was valued at USD 7.24 billion in 2021 and is expected to reach USD 12 Billion by 2027, growing at a CAGR of 8.77% during 2022-2027.
The following factors will drive the ulcerative colitis market growth during the forecast period:
Base Year: 2021
Forecast Year: 2022-2027
The study considers a detailed scenario of the present global ulcerative colitis market and its dynamics for the forecasted period. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent ones operating in the industry.
Key Vendors
Segmentation by Drug Class
Segmentation by Gender Type
Segmentation by Disease Type
Segmentation by Geography
CHAPTER – 1: ULCERATIVE COLITIS OVERVIEW
CHAPTER – 2: ULCERATIVE COLITIS EPIDEMIOLOGY & OVERVIEW
CHAPTER – 3: ULCERATIVE COLITIS MARKET SIZE & OVERVIEW
CHAPTER – 4: ULCERATIVE COLITIS MARKETED DRUGS OVERVIEW
CHAPTER – 5: ULCERATIVE COLITIS PIPELINE DRUGS OVERVIEW
CHAPTER – 6: ULCERATIVE COLITIS CLINICAL TRIALS OVERVIEW
CHAPTER – 7: ULCERATIVE COLITIS MARKET DYNAMICS
CHAPTER – 8: ULCERATIVE COLITIS COMPETITIVE LANDSCAPE
CHAPTER – 9: ULCERATIVE COLITIS MISCELLANEOUS
CHAPTER – 10: APPENDIX
LIST OF EXHIBITS
Exhibit 1: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN 8 MAJOR MARKETS (2018 – 2027)
Exhibit 2: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN 8 MAJOR MARKETS (2018 – 2020)
Exhibit 3: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN 8 MAJOR MARKETS (2021 – 2027)
Exhibit 4: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY DISEASE TYPE IN 8 MAJOR MARKETS (2018 – 2027)
Exhibit 5: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY SEVERITY TYPE IN 8 MAJOR MARKETS (2018 – 2027)
Exhibit 6: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY AGE GROUP IN 8 MAJOR MARKETS (2018 – 2027)
Exhibit 7: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY GENDER TYPE IN 8 MAJOR MARKETS (2018 – 2027)
Exhibit 8: HISTORIC & PROJECTED VOLUME OF PREVELANCE OF ULCERATIVE COLITIS BY DISEASE TYPE IN 8 MAJOR MARKETS (2018 – 2027)
Exhibit 9: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY SEVERITY TYPE IN 8 MAJOR MARKETS (2018 – 2027)
Exhibit 10: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY AGE GROUP IN 8 MAJOR MARKETS (2018 – 2027)
Exhibit 11: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY GENDER TYPE IN 8 MAJOR MARKETS (2018 – 2027)
Exhibit 12: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN US (2018 – 2027)
Exhibit 13: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN US (2018 – 2020)
Exhibit 14: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN US (2021 – 2027)
Exhibit 15: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY DISEASE TYPE IN US (2018 – 2027)
Exhibit 16: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY SEVERITY TYPE IN US (2018 – 2027)
Exhibit 17: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY AGE GROUP IN US (2018 – 2027)
Exhibit 18: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY GENDER TYPE IN US (2018 – 2027)
Exhibit 19: HISTORIC & PROJECTED VOLUME OF PREVELANCE OF ULCERATIVE COLITIS BY DISEASE TYPE IN US (2018 – 2027)
Exhibit 20: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY SEVERITY TYPE IN US (2018 – 2027)
Exhibit 21: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY AGE GROUP IN US (2018 – 2027)
Exhibit 22: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY GENDER TYPE IN US (2018 – 2027)
Exhibit 23: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN CHINA (2018 – 2027)
Exhibit 24: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN CHINA (2018 – 2020)
Exhibit 25: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN CHINA (2021 – 2027)
Exhibit 26: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY DISEASE TYPE IN CHINA (2018 – 2027)
Exhibit 27: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY SEVERITY TYPE IN CHINA (2018 – 2027)
Exhibit 28: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY AGE GROUP IN CHINA (2018 – 2027)
Exhibit 29: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY GENDER TYPE IN CHINA (2018 – 2027)
Exhibit 30: HISTORIC & PROJECTED VOLUME OF PREVELANCE OF ULCERATIVE COLITIS BY DISEASE TYPE IN CHINA (2018 – 2027)
Exhibit 31: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY SEVERITY TYPE IN CHINA (2018 – 2027)
Exhibit 32: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY AGE GROUP IN CHINA (2018 – 2027)
Exhibit 33: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY GENDER TYPE IN CHINA (2018 – 2027)
Exhibit 34: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN JAPAN (2018 – 2027)
Exhibit 35: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN JAPAN (2018 – 2020)
Exhibit 36: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN JAPAN (2021 – 2027)
Exhibit 37: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY DISEASE TYPE IN JAPAN (2018 – 2027)
Exhibit 38: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY SEVERITY TYPE IN JAPAN (2018 – 2027)
Exhibit 39: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY AGE GROUP IN JAPAN (2018 – 2027)
Exhibit 40: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY GENDER TYPE IN JAPAN (2018 – 2027)
Exhibit 41: HISTORIC & PROJECTED VOLUME OF PREVELANCE OF ULCERATIVE COLITIS BY DISEASE TYPE IN JAPAN (2018 – 2027)
Exhibit 42: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY SEVERITY TYPE IN JAPAN (2018 – 2027)
Exhibit 43: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY AGE GROUP IN JAPAN (2018 – 2027)
Exhibit 44: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY GENDER TYPE IN JAPAN (2018 – 2027)
Exhibit 45: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN GERMANY (2018 – 2027)
Exhibit 46: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN GERMANY (2018 – 2020)
Exhibit 47: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN GERMANY (2021 – 2027)
Exhibit 48: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY DISEASE TYPE IN GERMANY (2018 – 2027)
Exhibit 49: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY SEVERITY TYPE IN GERMANY (2018 – 2027)
Exhibit 50: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY AGE GROUP IN GERMANY (2018 – 2027)
Exhibit 51: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY GENDER TYPE IN GERMANY (2018 – 2027)
Exhibit 52: HISTORIC & PROJECTED VOLUME OF PREVELANCE OF ULCERATIVE COLITIS BY DISEASE TYPE IN GERMANY (2018 – 2027)
Exhibit 53: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY SEVERITY TYPE IN GERMANY (2018 – 2027)
Exhibit 54: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY AGE GROUP IN GERMANY (2018 – 2027)
Exhibit 55: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY GENDER TYPE IN GERMANY (2018 – 2027)
Exhibit 56: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN UK (2018 – 2027)
Exhibit 57: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN UK (2018 – 2020)
Exhibit 58: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN UK (2021 – 2027)
Exhibit 59: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY DISEASE TYPE IN UK (2018 – 2027)
Exhibit 60: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY SEVERITY TYPE IN UK (2018 – 2027)
Exhibit 61: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY AGE GROUP IN UK (2018 – 2027)
Exhibit 62: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY GENDER TYPE IN UK (2018 – 2027)
Exhibit 63: HISTORIC & PROJECTED VOLUME OF PREVELANCE OF ULCERATIVE COLITIS BY DISEASE TYPE IN UK (2018 – 2027)
Exhibit 64: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY SEVERITY TYPE IN UK (2018 – 2027)
Exhibit 65: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY AGE GROUP IN UK (2018 – 2027)
Exhibit 66: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY GENDER TYPE IN UK (2018 – 2027)
Exhibit 67: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN FRANCE (2018 – 2027)
Exhibit 68: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN FRANCE (2018 – 2020)
Exhibit 69: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN FRANCE (2021 – 2027)
Exhibit 70: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY DISEASE TYPE IN FRANCE (2018 – 2027)
Exhibit 71: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY SEVERITY TYPE IN FRANCE (2018 – 2027)
Exhibit 72: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY AGE GROUP IN FRANCE (2018 – 2027)
Exhibit 73: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY GENDER TYPE IN FRANCE (2018 – 2027)
Exhibit 74: HISTORIC & PROJECTED VOLUME OF PREVELANCE OF ULCERATIVE COLITIS BY DISEASE TYPE IN FRANCE (2018 – 2027)
Exhibit 75: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY SEVERITY TYPE IN FRANCE (2018 – 2027)
Exhibit 76: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY AGE GROUP IN FRANCE (2018 – 2027)
Exhibit 77: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY GENDER TYPE IN FRANCE (2018 – 2027)
Exhibit 78: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN ITALY (2018 – 2027)
Exhibit 79: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN ITALY (2018 – 2020)
Exhibit 80: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN ITALY (2021 – 2027)
Exhibit 81: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY DISEASE TYPE IN ITALY (2018 – 2027)
Exhibit 82: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY SEVERITY TYPE IN ITALY (2018 – 2027)
Exhibit 83: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY AGE GROUP IN ITALY (2018 – 2027)
Exhibit 84: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY GENDER TYPE IN ITALY (2018 – 2027)
Exhibit 85: HISTORIC & PROJECTED VOLUME OF PREVELANCE OF ULCERATIVE COLITIS BY DISEASE TYPE IN ITALY (2018 – 2027)
Exhibit 86: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY SEVERITY TYPE IN ITALY (2018 – 2027)
Exhibit 87: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY AGE GROUP IN ITALY (2018 – 2027)
Exhibit 88: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY GENDER TYPE IN ITALY (2018 – 2027)
Exhibit 89: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN SPAIN (2018 – 2027)
Exhibit 90: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN SPAIN (2018 – 2020)
Exhibit 91: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN SPAIN (2021 – 2027)
Exhibit 92: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY DISEASE TYPE IN SPAIN (2018 – 2027)
Exhibit 93: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY SEVERITY TYPE IN SPAIN (2018 – 2027)
Exhibit 94: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY AGE GROUP IN SPAIN (2018 – 2027)
Exhibit 95: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY GENDER TYPE IN SPAIN (2018 – 2027)
Exhibit 96: HISTORIC & PROJECTED VOLUME OF PREVELANCE OF ULCERATIVE COLITIS BY DISEASE TYPE IN SPAIN (2018 – 2027)
Exhibit 97: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY SEVERITY TYPE IN SPAIN (2018 – 2027)
Exhibit 98: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY AGE GROUP IN SPAIN (2018 – 2027)
Exhibit 99: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY GENDER TYPE IN SPAIN (2018 – 2027)
Exhibit 100: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET IN 8 MAJOR MARKETS (2021 – 2027)
Exhibit 101: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET SNAPSHOT IN 8 MAJOR MARKETS (2018 – 2020)
Exhibit 102: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY DISEASE TYPE IN 8 MAJOR MARKETS (2021 – 2027)
Exhibit 103: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY GENDER TYPE IN 8 MAJOR MARKETS (2021 – 2027)
Exhibit 104: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY DRUG CLASS IN 8 MAJOR MARKETS (2021 – 2027)
Exhibit 105: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET IN US (2021 – 2027)
Exhibit 106: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET SNAPSHOT IN US (2018 – 2020)
Exhibit 107: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY DISEASE TYPE IN US (2021 – 2027)
Exhibit 108: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY GENDER TYPE IN US (2021 – 2027)
Exhibit 109: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY DRUG CLASS IN US (2021 – 2027)
Exhibit 110: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET IN CHINA (2021 – 2027)
Exhibit 111: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET SNAPSHOT IN CHINA (2018 – 2020)
Exhibit 112: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY DISEASE TYPE IN CHINA (2021 – 2027)
Exhibit 113: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY GENDER TYPE IN CHINA (2021 – 2027)
Exhibit 114: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY DRUG CLASS IN CHINA (2021 – 2027)
Exhibit 115: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET IN GERMANY (2021 – 2027)
Exhibit 116: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET SNAPSHOT IN GERMANY (2018 – 2020)
Exhibit 117: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY DISEASE TYPE IN GERMANY (2021 – 2027)
Exhibit 118: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY GENDER TYPE IN GERMANY (2021 – 2027)
Exhibit 119: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY DRUG CLASS IN GERMANY (2021 – 2027)
Exhibit 120: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET IN JAPAN (2021 – 2027)
Exhibit 121: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET SNAPSHOT IN JAPAN (2018 – 2020)
Exhibit 122: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY DISEASE TYPE IN JAPAN (2021 – 2027)
Exhibit 123: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY GENDER TYPE IN JAPAN (2021 – 2027)
Exhibit 124: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY DRUG CLASS IN JAPAN (2021 – 2027)
Exhibit 125: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET IN FRANCE (2021 – 2027)
Exhibit 126: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET SNAPSHOT IN FRANCE (2018 – 2020)
Exhibit 127: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY DISEASE TYPE IN FRANCE (2021 – 2027)
Exhibit 128: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY GENDER TYPE IN FRANCE (2021 – 2027)
Exhibit 129: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY DRUG CLASS IN FRANCE (2021 – 2027)
Exhibit 130: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET IN ITALY (2021 – 2027)
Exhibit 131: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET SNAPSHOT IN ITALY (2018 – 2020)
Exhibit 132: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY DISEASE TYPE IN ITALY (2021 – 2027)
Exhibit 133: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY GENDER TYPE IN ITALY (2021 – 2027)
Exhibit 134: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY DRUG CLASS IN ITALY (2021 – 2027)
Exhibit 135: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET IN UK (2021 – 2027)
Exhibit 136: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET SNAPSHOT IN UK (2018 – 2020)
Exhibit 137: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY DISEASE TYPE IN UK (2021 – 2027)
Exhibit 138: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY GENDER TYPE IN UK (2021 – 2027)
Exhibit 139: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY DRUG CLASS IN UK (2021 – 2027)
Exhibit 140: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET IN SPAIN (2021 – 2027)
Exhibit 141: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET SNAPSHOT IN SPAIN (2018 – 2020)
Exhibit 142: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY DISEASE TYPE IN SPAIN (2021 – 2027)
Exhibit 143: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY GENDER TYPE IN SPAIN (2021 – 2027)
Exhibit 144: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY DRUG CLASS IN SPAIN (2021 – 2027)
Exhibit 145: MARKETED DRUGS OVERVIEW IN ULCERATIVE COLITIS THERAPEUTICS MARKET
Exhibit 146: MARKETED DRUGS OVERVIEW SNAPSHOT IN ULCERATIVE COLITIS THERAPEUTICS MARKET
Exhibit 147: PIPELINE DRUGS OVERVIEW IN ULCERATIVE COLITIS THERAPEUTICS MARKET
Exhibit 148: ULCERATIVE COLITIS PIPELINE DRUGS OVERVIEW BY DISEASE TYPE
Exhibit 149: ULCERATIVE COLITIS PIPELINE DRUGS OVERVIEW BY DEVELOPMENT PHASE
Exhibit 150: ULCERATIVE COLITIS PIPELINE DRUGS OVERVIEW BY ROUTE OF ADMINISTRATION
Exhibit 151: ULCERATIVE COLITIS PIPELINE DRUGS OVERVIEW BY MECHANISM OF ACTION
Exhibit 152: ULCERATIVE COLITIS PIPELINE DRUGS OVERVIEW BY MOLECULE TYPE
Exhibit 153: ULCERATIVE COLITIS PIPELINE DRUGS OVERVIEW BY GEOGRAPHY TYPE
Exhibit 154: ULCERATIVE COLITIS CLINICAL TRIAL ANALYSIS SNAPSHOT
Exhibit 155: ULCERATIVE COLITIS CLINICAL TRIAL ANALYSIS SNAPSHOT BY RECRUITMENT STATUS
Exhibit 156: ULCERATIVE COLITIS CLINICAL TRIAL ANALYSIS SNAPSHOT BY PRODUCT TYPE
Exhibit 157: ULCERATIVE COLITIS CLINICAL TRIAL ANALYSIS SNAPSHOT BY ROUTE OF ADMINISTRATION
Exhibit 158: ULCERATIVE COLITIS CLINICAL TRIAL ANALYSIS SNAPSHOT BY MOLECULE TYPE
Exhibit 159: ULCERATIVE COLITIS CLINICAL TRIAL ANALYSIS SNAPSHOT BY GEOGRAPHY TYPE
Exhibit 160: COMPETITIVE ASSESSMENT OF ULCERATIVE COLITIS THERAPEUTICS MARKET
TABLES
Table 1: KEY MARKET DRIVERS IN ULCERATIVE COLITIS THERAPEUTICS MARKET
Table 2: KEY MARKET CONSTRAINTS IN ULCERATIVE COLITIS THERAPEUTICS MARKET
Table 3: KEY MARKET TRENDS IN ULCERATIVE COLITIS THERAPEUTICS MARKET
Table 4: KEY TENTATIVE TIMELINE APPROVALS OF PIPELINE DRUHS IN ULCERATIVE COLITIS
Table 5: KEY REGULATORY DESIGNATIONS OF PIPELINE DRUHS IN ULCERATIVE COLITIS
Table 6: KEY MILESTONES IN ULCERATIVE COLITIS THERAPEUTICS MARKET
Table 7: KEY DEALS & COLLABORATIONS IN ULCERATIVE COLITIS THERAPEUTICS MARKET
Table 8: KEY INACTIVE/DISCONTINUED PRODUCTS IN ULCERATIVE COLITIS THERAPEUTICS MARKET
Single User Licence
5 User Licence
Corporate Licence
Datasheet Licence
"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."
